Exploratory Study of Plaque Regression

Cerenis Therapeutics, SA10 enrolled

Overview

Despite the availability of several classes of very effective drugs available to treat heterozygous Familial Hypercholesterolemia (HeFH), there remains a large unmet medical need for new, effective and well tolerated therapies. There are a number of therapies given on a chronic basis to reduce long term risk, such as statins, fibrates, niacin, omega 3 fatty acids, resins, cholesterol absorption inhibitors and antiplatelet or anticoagulant drugs, but subjects with heterozygous Familial Hypercholesterolemia remain at high risk for cardiovascular events. There is still a need for acute therapies that can lead to rapid pacification of unstable plaque in order to reduce the risk of these events. This study will assess the effects of CER-001 , a recombinant human Apo-A-1 based HDL mimetic, on indices of atherosclerotic plaque progression and regression as assessed by 3Tesla MRI (3TMRI)and intravascular ultrasound (IVUS) evaluations in patients with HeFH.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or Female subjects at least 18 years old * Subject presents heterozygous FH, known CHD and receiving maximally tolerated lipid modifying therapy, at stable doses for at least 3 months * LDL-C of \> 110 mg/dl * Angiographic evidence of coronary artery disease with suitable "target" coronary artery for IVUS Exclusion Criteria: * Confirmed diagnosis of homozygous FH * Significant health problems (other than cardiovascular disease) in the recent past including blood disorders, cancer, or digestive problems * Female subjects not meeting the study definition of non child-bearing potential * Use of an investigational agent within 30 days of the first CER-001 dose * Receiving current lipid apheresis

Outcomes

Primary Outcomes

Change in Total Plaque Volume

Nominal change in total plaque volume (ACTPV), as assessed by 3D IVUS, from the baseline measurement to the follow-up taken \~3 weeks following the final dose of study medication (approximately 10 weeks after the baseline assessment)

Time frame: Baseline and 3 weeks post final dose

Secondary Outcomes

Percent Change in Plaque Volume

Percent change in total plaque volume (PCTPV), as assessed by IVUS, from the baseline measurement to the follow up taken approximately 3 weeks following the final dose of study medication (approximately 10 weeks after the baseline assessment)

Time frame: Baseline and 3 weeks post final dose

Change in carotid plaque volume

Percent change in total carotid plaque volume, as assessed by 3TMRI, from the baseline measurement to the follow up taken approximately 3 weeks following the final dose of study medication

Time frame: Baseline and 3 weeks post final dose

Exploratory Study of Plaque Regression

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes